{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:38:54Z","timestamp":1791923934180,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03168-8","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T15:03:02Z","timestamp":1661353382000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Secondary diabetes mellitus due to primary aldosteronism"],"prefix":"10.1007","volume":"79","author":[{"given":"Melpomeni","family":"Moustaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni C.","family":"Vakali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Vryonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"3168_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3168_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","volume":"273","author":"JW Conn","year":"1965","unstructured":"J.W. Conn, Hypertension, the potassium ion and impaired carbohydrate tolerance. N. Eng. J. Med. 273, 1135\u20131143 (1965)","journal-title":"N. Eng. J. Med."},{"key":"3168_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1530\/EJE-15-0450","volume":"173","author":"G Hanslik","year":"2015","unstructured":"G. Hanslik, H. Wallaschofski, A. Dietz, A. Riester, M. Reincke, B. Allolio et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn\u2019s Registry. Eur. J. Endocrinol. 173, 665\u2013675 (2015)","journal-title":"Eur. J. Endocrinol."},{"key":"3168_CR4","doi-asserted-by":"publisher","unstructured":"M.K. Kwak, J.Y. Lee, B.J. Kim, S.H. Lee, J.M. Koh, Effects of primary aldosteronism and different therapeutic modalities on glucose metabolism. J. Clin. Med. (2019). https:\/\/doi.org\/10.3390\/jcm8122194","DOI":"10.3390\/jcm8122194"},{"key":"3168_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2337\/dc18-1293","volume":"42","author":"Y Akehi","year":"2019","unstructured":"Y. Akehi, T. Yanase, R. Motonaga, H. Umakoshi, M. Tsuiki, Y. Takeda et al. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care 42, 938\u2013945 (2019)","journal-title":"Diabetes Care"},{"key":"3168_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0029-1246189","volume":"42","author":"M Reincke","year":"2010","unstructured":"M. Reincke, C. Meisinger, R. Holle, M. Quinkler, S. Hahner, F. Beuschlein et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn\u2019s registry. Horm. Metab. Res. 42, 435\u2013439 (2010)","journal-title":"Horm. Metab. Res."},{"key":"3168_CR7","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"C. Catena, R. Lapenna, S. Baroselli, E. Nadalini, G.L. Colussi, M. Novello et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 91, 3457\u20133463 (2006)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3168_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.jhh.1001292","volume":"16","author":"M Haluzik","year":"2002","unstructured":"M. Haluzik, G.S. Sindelka, J. Widimsky, M. Prazny, T. Zelinka, J.S. Skrha, Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J. Hum. Hypertens. 16, 41\u201345 (2002)","journal-title":"J. Hum. Hypertens."},{"key":"3168_CR9","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1210\/jc.2012-3934","volume":"9","author":"E Fischer","year":"2013","unstructured":"E. Fischer, C. Adolf, A. Pallauf, C. Then, M. Bidlingmaier, F. Beuschlein et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J. Clin. Endocrinol. Metab. 9, 2513\u20132520 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3168_CR10","doi-asserted-by":"publisher","unstructured":"M. Han, X. Cao, C. Zhao, L. Yang, N. Yin, P. Shen, et al. Assessment of glycometabolism impairment and glucose variability using flash glucose monitoring system in patients with adrenal diseases. Front. Endocrinol. (2020). https:\/\/doi.org\/10.3389\/fendo.2020.544752","DOI":"10.3389\/fendo.2020.544752"},{"key":"3168_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11845-013-1007-x","volume":"183","author":"W Chen","year":"2014","unstructured":"W. Chen, F. Li, C. He, Y. Zhu, W. Tan, Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis. Ir. J. Med. Sci. 183, 283\u2013291 (2014)","journal-title":"Ir. J. Med. Sci."},{"key":"3168_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3168_CR13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.33549\/physiolres.930123","volume":"50","author":"J Widimsky","year":"2001","unstructured":"J. Widimsky, B. Strauch, J. Skrha, Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol. Res. 50, 603\u2013607 (2001)","journal-title":"Physiol. Res."},{"key":"3168_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406223211066727","volume":"13","author":"CH Tsai","year":"2022","unstructured":"C.H. Tsai, X.M. Wu, C.W. Liao, Z.W. Chen, C.T. Pan, Y.Y. Chang et al. Diabetes mellitus is associated with worse baseline and less post-treatment recovery of arterial stiffness in patients with primary aldosteronism. Ther. Adv. Chronic Dis. 13, 1\u201314 (2022)","journal-title":"Ther. Adv. Chronic Dis."},{"key":"3168_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G Giacchetti","year":"2007","unstructured":"G. Giacchetti, V. Ronconi, F. Turchi, L. Agostinelli, F. Mantero, S. Rilli et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25, 177\u2013186 (2007)","journal-title":"J. Hypertens."},{"key":"3168_CR16","doi-asserted-by":"publisher","unstructured":"W. Arlt, K. Lang, A.J. Sitch, A.S. Dietz, Y. Rhayem, I. Bancos, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight (2017). https:\/\/doi.org\/10.1172\/jci.insight.93136","DOI":"10.1172\/jci.insight.93136"},{"key":"3168_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1055\/a-1164-1944","volume":"52","author":"L Handgriff","year":"2020","unstructured":"L. Handgriff, C. Adolf, D.A. Heinrich, L. Braun, N. Nirschl, L. Sturm et al. The impact of glucocorticoid co-secretion in primary aldosteronism on thyroid autoantibody titers during the course of disease. Horm. Metab. 52, 404\u2013411 (2020)","journal-title":"Horm. Metab."},{"key":"3168_CR18","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1210\/jc.2019-00299","volume":"104","author":"J Gerards","year":"2019","unstructured":"J. Gerards, D.A. Heinrich, C. Adolf, C. Meisinger, W. Rathmann, L. Sturm et al. Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. J. Clin. Endocrinol. Metab. 104, 3192\u20133202 (2019)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3168_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10641963.2016.1182176","volume":"38","author":"D Watanabe","year":"2016","unstructured":"D. Watanabe, M. Yatabe, A. Ichihara, Evaluation of insulin sensitivity and secretion in primary aldosteronism. Clin. Exp. Hypertens. 38, 613\u2013617 (2016)","journal-title":"Clin. Exp. Hypertens."},{"key":"3168_CR20","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc07-0525","volume":"30","author":"GL Colussi","year":"2007","unstructured":"G.L. Colussi, C. Catena, R. Lapenna, E. Nadalini, A. Chiuch, L.A. Sechi, Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30, 2349\u20132354 (2007)","journal-title":"Diabetes Care"},{"key":"3168_CR21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1136\/hrt.2009.173344","volume":"95","author":"EM Freel","year":"2009","unstructured":"E.M. Freel, I.K. Tsorlalis, J.D. Lewsey, R. Latini, A.P. Maggioni, S. Solomon et al. Aldosterone status associated with insulin resistance in patients with heart failure\u2014data from the ALOFT study. Heart 95, 1920\u20131924 (2009)","journal-title":"Heart"},{"key":"3168_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","volume":"60","author":"TL Goodfriend","year":"1999","unstructured":"T.L. Goodfriend, B.M. Egan, D.E. Kelley, Plasma aldlosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins, Leykot. Essent. Fat. Acids 60, 401\u2013405 (1999)","journal-title":"Prostaglandins, Leykot. Essent. Fat. Acids"},{"key":"3168_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/HYPERTENSIONAHA.111.180521","volume":"58","author":"E Kumagai","year":"2011","unstructured":"E. Kumagai, H. Adachi, D.R. Jacobs, Y. Hirai, M. Enomoto, A. Fukami et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension 58, 1043\u20131048 (2011)","journal-title":"Hypertension"},{"key":"3168_CR24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/0024-3205(92)90062-T","volume":"50","author":"D Petrasek","year":"1992","unstructured":"D. Petrasek, G. Jensen, M. Tuck, N. Stern, In vitro effects of insulin on aldosterone production in rat zone glomerulosa cells. Life Sci. 50, 1781\u20131787 (1992)","journal-title":"Life Sci."},{"key":"3168_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0895-7061(02)02257-4","volume":"15","author":"G Giacchetti","year":"2002","unstructured":"G. Giacchetti, E. Faloia, B. Mariniello, C. Sardu, C. Gatti, M.A. Camilloni et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am. J. Hypertens. 15, 381\u2013388 (2002)","journal-title":"Am. J. Hypertens."},{"key":"3168_CR26","doi-asserted-by":"publisher","unstructured":"G. Lastra, A. Whaley-Connell, C. Manrique, J. Habibi, A.A. Gutweiler, L. Appesh, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am. J. Physiol. Endocrinol. Metabol. (2008). https:\/\/doi.org\/10.1152\/ajpendo.00258.2007","DOI":"10.1152\/ajpendo.00258.2007"},{"key":"3168_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11010-012-1452-2","volume":"372","author":"J Selvaraj","year":"2013","unstructured":"J. Selvaraj, S. Sathish, C. Mayilvanan, K. Balasubramanian, Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Mol. Cell. Biochem. 372, 113\u2013126 (2013)","journal-title":"Mol. Cell. Biochem."},{"key":"3168_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0960-0760(03)00072-4","volume":"84","author":"C Calle","year":"2003","unstructured":"C. Calle, J. Campion, M. Garcia-Arencibia, B. Maestro, N. Davila, Transcriptional inhibition of the human insulin receptor gene by aldosterone. J. Steroid Biochem. Mol. Biol. 84, 543\u2013553 (2003)","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"3168_CR29","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1172\/JCI116424","volume":"91","author":"F Giorgino","year":"1993","unstructured":"F. Giorgino, A. Almahfouz, L.J. Goodyear, R.J. Smith, Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J. Clin. Investig. 91, 2020\u20132030 (1993)","journal-title":"J. Clin. Investig."},{"key":"3168_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.107.093955","volume":"50","author":"H Hitomi","year":"2007","unstructured":"H. Hitomi, H. Kiyomoto, A. Nishiyama, T. Hara, K. Moriwaki, K. Kaifu et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50, 750\u2013755 (2007)","journal-title":"Hypertension"},{"key":"3168_CR31","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1210\/en.2008-1018","volume":"150","author":"T Wada","year":"2009","unstructured":"T. Wada, S. Ohshima, E. Fujisawa, D. Koya, H. Tsuneki, T. Sasaoka, Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 150, 1662\u20131669 (2009)","journal-title":"Endocrinology"},{"key":"3168_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A Hirata","year":"2009","unstructured":"A. Hirata, N. Maeda, A. Hiuge, T. Hibuse, K. Fujita, T. Okada et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc. Res. 84, 164\u2013172 (2009)","journal-title":"Cardiovasc. Res."},{"key":"3168_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1055\/s-0031-1277226","volume":"43","author":"P Li","year":"2011","unstructured":"P. Li, X.N. Zhang, C.M. Pan, F. Sun, D.L. Zhu, H.D. Song et al. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm. Metab. Res. 43, 464\u2013469 (2011)","journal-title":"Horm. Metab. Res."},{"key":"3168_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.amjhyper.2007.03.012","volume":"20","author":"F Fallo","year":"2007","unstructured":"F. Fallo, P. della Mea, N. Sonino, C. Bertello, M. Ermani, R. Vettor et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 20, 855\u2013861 (2007)","journal-title":"Am. J. Hypertens."},{"key":"3168_CR35","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","volume":"117","author":"C Guo","year":"2008","unstructured":"C. Guo, V. Ricchiuti, B.Q. Lian, T.M. Yao, P. Coutinho, J.R. Romero et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-\u03b3, and proinflammatory adipokines. Circulation 117, 2253\u20132261 (2008)","journal-title":"Circulation"},{"key":"3168_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.mce.2012.02.007","volume":"355","author":"TA Williams","year":"2002","unstructured":"T.A. Williams, S. Monticone, R. Urbanet, C. Bertello, G. Giraudo, R. Vettor et al. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol. Cell. Endocrinol. 355, 162\u2013168 (2002)","journal-title":"Mol. Cell. Endocrinol."},{"key":"3168_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/s-2005-870240","volume":"37","author":"D Kraus","year":"2005","unstructured":"D. Kraus, J. Jager, B. Meier, M. Fasshauer, J. Klein, Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm. Metab. Res. 37, 455\u2013459 (2005)","journal-title":"Horm. Metab. Res."},{"key":"3168_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1055\/s-2007-978789","volume":"31","author":"DJ Torpy","year":"1999","unstructured":"D.J. Torpy, S.R. Bornstein, W. Taylor, R. Tauchnitz, R.D. Gordon, Leptin levels are suppressed in primary aldosteronism. Horm. Metab. Res. 31, 533\u2013536 (1999)","journal-title":"Horm. Metab. Res."},{"key":"3168_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MNH.0000000000000384","volume":"27","author":"JL Faulkner","year":"2018","unstructured":"J.L. Faulkner, T. Bruder-Nascimento, E.J. Belin De Chantemele, The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease. Curr. Opin. Nephrol. Hypertens. 27, 63\u201369 (2018)","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"3168_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1507\/endocrj.51.243","volume":"51","author":"R Yamashita","year":"2004","unstructured":"R. Yamashita, T. Kikuchi, Y. Mori, K. Aoki, Y. Kaburagi, K. Yasuda et al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr. J. 51, 243\u2013251 (2004)","journal-title":"Endocr. J."},{"key":"3168_CR41","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bbrc.2006.02.065","volume":"342","author":"G Liu","year":"2006","unstructured":"G. Liu, M. Grifman, B. Keily, J.E. Chatterton, F.W. Staal, Q.X. Li, Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem. Biophys. Res. Commun. 342, 1291\u20131296 (2006)","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3168_CR42","doi-asserted-by":"publisher","unstructured":"Y. Chen, X. Chen, Q. Chen, C. Yu, Non-alcoholic fatty liver disease and hypokalemia in primary aldosteronism among Chinese population. Front. Endocrinol. (2021). https:\/\/doi.org\/10.3389\/fendo.2021.565714","DOI":"10.3389\/fendo.2021.565714"},{"key":"3168_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ajh.2009.206","volume":"23","author":"F Fallo","year":"2010","unstructured":"F. Fallo, A. Dalla Pozza, M. Tecchio, F. Tona, N. Sonino, M. Ermani et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am. J. Hypertens. 23, 2\u20135 (2010)","journal-title":"Am. J. Hypertens."},{"key":"3168_CR44","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1210\/en.2009-0869","volume":"151","author":"T Wada","year":"2010","unstructured":"T. Wada, H. Kenmochi, Y. Miyashita, M. Sasaki, M. Ojima, M. Sasahara et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151, 2040\u20132049 (2010)","journal-title":"Endocrinology"},{"key":"3168_CR45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/MEG.0b013e328360554a","volume":"25","author":"A Gamliel-Lazarovich","year":"2013","unstructured":"A. Gamliel-Lazarovich, A. Raz-Pasteur, R. Coleman, S. Keidar, The effects of aldosterone on diet-induced fatty liver formation in male C57BL\/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. Eur. J. Gastroenterol. Hepatol. 25, 1086\u20131092 (2013)","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"3168_CR46","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1152\/ajpendo.00419.2013","volume":"305","author":"T Wada","year":"2013","unstructured":"T. Wada, Y. Miyashita, M. Sasaki, Y. Aruga, Y. Nakamura, Y. Ishii et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am. J. Physiol. Endocrinol. Metab. 305, 1415\u20131425 (2013)","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"3168_CR47","first-page":"407","volume":"26","author":"R Noguchi","year":"2010","unstructured":"R. Noguchi, H. Yoshiji, Y. Ikenaka, K. Kaji, Y. Shirai, Y. Aihara et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int. J. Mol. Med. 26, 407\u2013413 (2010)","journal-title":"Int. J. Mol. Med."},{"key":"3168_CR48","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1161\/HYPERTENSIONAHA.119.13922","volume":"75","author":"GK Adler","year":"2020","unstructured":"G.K. Adler, G.R. Murray, A.F. Turcu, H. Nian, C. Yu, C.C. Solorzano et al. Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension 75, 1251\u20131259 (2020)","journal-title":"Hypertension"},{"key":"3168_CR49","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","volume":"54","author":"JM Luther","year":"2011","unstructured":"J.M. Luther, P. Luo, M.T. Kreger, M. Brissova, C. Dai, T.T. Whitfield et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54, 2152\u20132163 (2011)","journal-title":"Diabetologia"},{"key":"3168_CR50","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","volume":"25","author":"LM Mosso","year":"2007","unstructured":"L.M. Mosso, C.A. Carvajal, A. Maiz, E.H. Ortiz, C.R. Castillo, R.A. Artigas et al. A possible association between primary aldosteronism and a lower b-cell function. J. Hypertens. 25, 2125\u20132130 (2007)","journal-title":"J. Hypertens."},{"key":"3168_CR51","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1507\/endocrj.EJ16-0500","volume":"64","author":"Y Tsurutani","year":"2017","unstructured":"Y. Tsurutani, C. Sugisawa, A. Ishida, K. Inoue, J. Saito, M. Omura et al. Aldosterone excess may inhibit insulin secretion: a comparative study on glucose metabolism pre- and post-adrenalectomy in patients with primary aldosteronism. Endocr. J. 64, 339\u2013346 (2017)","journal-title":"Endocr. J."},{"key":"3168_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.diabet.2019.10.002","volume":"46","author":"H Komada","year":"2020","unstructured":"H. Komada, Y. Hirota, A. So, T. Nakamura, Y. Okuno, H. Fukuoka et al. Insulin secretion and sensitivity before and after surgical treatment for aldosterone-producing adenoma. Diabetes Metab. 46, 236\u2013242 (2020)","journal-title":"Diabetes Metab."},{"key":"3168_CR53","doi-asserted-by":"publisher","unstructured":"F. Chen, J. Liu, Y. Wang, T. Wu, W. Shan, Y. Zhu, et al. Aldosterone induces clonal \u03b2-cell failure through glucocorticoid receptor. Sci. Rep. (2015). https:\/\/doi.org\/10.1038\/srep13215","DOI":"10.1038\/srep13215"},{"key":"3168_CR54","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1210\/en.2013-1115","volume":"154","author":"HM Jin","year":"2013","unstructured":"H.M. Jin, D.C. Zhou, H.F. Gu, Q.Y. Qiao, S.K. Fu, X.L. Liu et al. Antioxidant N-acetylcysteine protects pancreatic \u03b2-cells against aldosterone-induced oxidative stress and apoptosis in female db\/db mice and insulin-producing MIN6 cells. Endocrinology 154, 4068\u20134077 (2013)","journal-title":"Endocrinology"},{"key":"3168_CR55","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1152\/ajpregu.91000.2008","volume":"298","author":"JF Ndisang","year":"2010","unstructured":"J.F. Ndisang, A. Jadhav, The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R211\u2013R223 (2010)","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"3168_CR56","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.2337\/diabetes.48.12.2398","volume":"48","author":"H Kaneto","year":"1999","unstructured":"H. Kaneto, Y. Kajimoto, J.I. Miyagawa, T.A. Matsuoka, Y. Fujitani, Y. Umayahara et al. Beneficial effects of antioxidants in diabetes possible protection of pancreatic b-cells against glucose toxicity. Diabetes 48, 2398\u20132406 (1999)","journal-title":"Diabetes"},{"key":"3168_CR57","doi-asserted-by":"publisher","first-page":"11107","DOI":"10.1074\/jbc.M410345200","volume":"280","author":"JS Harmon","year":"2005","unstructured":"J.S. Harmon, R. Stein, R.P. Robertson, Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J. Biol. Chem. 280, 11107\u201311113 (2005)","journal-title":"J. Biol. Chem."},{"key":"3168_CR58","doi-asserted-by":"publisher","first-page":"32413","DOI":"10.1074\/jbc.M506000200","volume":"280","author":"DK Hagman","year":"2005","unstructured":"D.K. Hagman, L.B. Hays, S.D. Parazzoli, V. Poitout, Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing Mafa expression in isolated rat islets of langerhans. J. Biol. Chem. 280, 32413\u201332418 (2005)","journal-title":"J. Biol. Chem."},{"key":"3168_CR59","doi-asserted-by":"publisher","unstructured":"R. Goto, T. Kondo, K. Ono, S. Kitano, N. Miyakawa, T. Watanabe, et al. Mineralocorticoid receptor may regulate glucose homeostasis through the induction of interleukin-6 and glucagon-like peptide-1 in pancreatic islets. J. Clin. Med. (2019). https:\/\/doi.org\/10.3390\/jcm8050674","DOI":"10.3390\/jcm8050674"},{"key":"3168_CR60","first-page":"21","volume":"108","author":"G Sindelka","year":"2000","unstructured":"G. Sindelka, J. Widimsky, T. Haas, M. Prazny, J. Hilgertova, J. Skrha, Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp. Clin. Endocrinol. Diabetes 108, 21\u201325 (2000)","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"3168_CR61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.33549\/physiolres.930298","volume":"52","author":"B Strauch","year":"2003","unstructured":"B. Strauch, J. Widimsky, G. Sindelka, J. Skrha, Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol. Res. 52, 503\u2013506 (2003)","journal-title":"Physiol. Res."},{"key":"3168_CR62","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/jdi.13312","volume":"11","author":"M Okazaki-Hada","year":"2020","unstructured":"M. Okazaki-Hada, A. Moriya, M. Nagao, S. Oikawa, I. Fukuda, H. Sugihara, Different pathogenesis of glucose intolerance in two subtypes of primary aldosteronism: aldosterone-producing adenoma and idiopathic hyperaldosteronism. J. Diabetes Investig. 11, 1511\u20131519 (2020)","journal-title":"J. Diabetes Investig."},{"key":"3168_CR63","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3803\/EnM.2020.797","volume":"35","author":"YF Lin","year":"2020","unstructured":"Y.F. Lin, K.Y. Peng, C.H. Chang, Y.H. Hu, V.C. Wu, S.D. Chung, Changes in glucose metabolism after adrenalectomy or treatment with a mineralocorticoid receptor antagonist for primary aldosteronism. Endocrinol. Metab. 35, 838\u2013846 (2020)","journal-title":"Endocrinol. Metab."},{"key":"3168_CR64","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/HJH.0000000000001361","volume":"35","author":"VC Wu","year":"2017","unstructured":"V.C. Wu, S.C.J. Chueh, L. Chen, C.H. Chang, Y.H. Hu, Y.H. Lin et al. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J. Hypertens. 35, 1698\u20131708 (2017)","journal-title":"J. Hypertens."},{"key":"3168_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6, 51\u201359 (2018)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3168_CR66","doi-asserted-by":"publisher","unstructured":"J.V. Zhao, L. Xu, S.L. Lin, C.M. Schooling, Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. J. Am. Soc. Hypertens. (2016). https:\/\/doi.org\/10.1016\/j.jash.2016.05.013","DOI":"10.1016\/j.jash.2016.05.013"},{"key":"3168_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08037051.2021.1880881","volume":"30","author":"M Lin","year":"2021","unstructured":"M. Lin, M. Heizati, L. Wang, M. Nurula, Z. Yang, Z. Wang et al. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. Blood Press 30, 145\u2013153 (2021)","journal-title":"Blood Press"},{"key":"3168_CR68","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","volume":"14","author":"D Preiss","year":"2012","unstructured":"D. Preiss, D.J. van Veldhuisen, N. Sattar, H. Krum, K. Swedberg, H. Shi et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur. J. Heart Fail. 14, 909\u2013915 (2012)","journal-title":"Eur. J. Heart Fail."},{"key":"3168_CR69","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/jhh.2014.19","volume":"28","author":"EM McMurray","year":"2014","unstructured":"E.M. McMurray, I.R. Wallace, C. Ennis, S.J. Hunter, A.B. Atkinson, P.M. Bell, Effect of eplerenone on insulin action in essential hypertension: a randomised, controlled, crossover study. J. Hum. Hypertens. 28, 575\u2013578 (2014)","journal-title":"J. Hum. Hypertens."},{"key":"3168_CR70","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1292\/jvms.12-0007","volume":"74","author":"T Homma","year":"2012","unstructured":"T. Homma, M. Fujisawa, K. Arai, M. Ishii, T. Sada, M. Ikeda, Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. J. Vet. Med. Sci. 74, 1015\u20131022 (2012)","journal-title":"J. Vet. Med. Sci."},{"issue":"Suppl 1","key":"3168_CR71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0753-3322(00)80044-X","volume":"54","author":"T Saito","year":"2000","unstructured":"T. Saito, S. Satoh, S. Kawasaki, K. Mukasa, S. Itoh, T. Yamakawa et al. Three patients with adrenal tumors having been treated simply for diabetes mellitus. 54. Biomed. Pharmacother. 54(Suppl 1), 198\u2013202 (2000)","journal-title":"Biomed. Pharmacother."},{"key":"3168_CR72","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s42000-019-00147-z","volume":"19","author":"KJ Ioakim","year":"2020","unstructured":"K.J. Ioakim, G.I. Sydney, S.A. Paschou, Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management. Hormones 19, 135\u2013143 (2020)","journal-title":"Hormones"},{"key":"3168_CR73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MAJ.0b013e31827ad893","volume":"345","author":"Y Kashiwagi","year":"2013","unstructured":"Y. Kashiwagi, Y. Mizuno, E. Harada, M. Shono, S. Morita, M. Yoshimura et al. Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. Am. J. Med. Sci. 345, 497\u2013500 (2013)","journal-title":"Am. J. Med. Sci."},{"key":"3168_CR74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s42000-019-00167-9","volume":"19","author":"S Fountoulakis","year":"2020","unstructured":"S. Fountoulakis, L. Papanastasiou, N. Voulgaris, T. Kounadi, A. Markou, G.P. Chrousos et al. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally? Hormones 19, 223\u2013232 (2020)","journal-title":"Hormones"},{"key":"3168_CR75","doi-asserted-by":"publisher","unstructured":"T. Sawamura, S. Karashima, S. Nagase, H. Nambo, E. Shimizu, T. Higashitani, et al. Effect of sodium\u2013glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study. BMC Endocr. Disord. (2020). https:\/\/doi.org\/10.1186\/s12902-020-00656-8","DOI":"10.1186\/s12902-020-00656-8"},{"key":"3168_CR76","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"JB Buse","year":"2020","unstructured":"J.B. Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 221\u2013228 (2020)","journal-title":"Diabetologia"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03168-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03168-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03168-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T13:28:59Z","timestamp":1727875739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03168-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["3168"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03168-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}